Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise for Hard-to-Treat cancers

NCT ID NCT04250155

Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take part in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

195 people

The number who actually took part.

Started

Mar 2020

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key General Inclusion Criteria * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Life expectancy \>/= 12 weeks * Adequate hematologic and end-organ function * For participants receiving therapeutic anticoagulation: stable anticoagulant regimen * Negative serum pregnancy test for women of childbearing potential * Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Availability of representative tumor specimens Key General Exclusion Criteria * Pregnant or breastfeeding, or intending to become pregnant during the study * Significant cardiovascular disease * Current treatment with medications that prolong the QT interval * Known clinically significant liver disease * Poorly controlled Type 2 diabetes mellitus * Symptomatic, untreated, or actively progressing CNS metastases * History of leptomeningeal disease * History of malignancy other than disease under study within 3 years prior to screening * Active or history of autoimmune disease or immune deficiency * Active tuberculosis, hepatitis B, hepatitis C, or known/suspected Epstein Barr virus infection * Positive for HIV infection * Prior allogeneic stem cell or solid organ transplantation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumors

Contacts and locations

Locations

  • Asan Medical Center - PPDS

    Seoul, 05505, South Korea

  • City of Hope Comprehensive Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • Clinica Universidad de Navarra-Madrid

    Madrid, 28027, Spain

  • Clinica Universitaria de Navarra

    Pamplona, Navarre, 31008, Spain

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Lombardy, 20133, Italy

  • GasthuisZusters Antwerpen

    Wilrijk, Antwerp, 2610, Belgium

  • Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis

    Amsterdam, North Holland, 1066 CX, Netherlands

  • Honor Health Research Institute

    Scottsdale, Arizona, 85258, United States

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital de Clinicas de Porto Alegre HCPA PPDS

    Porto Alegre, Rio Grande do Sul, 90560-030, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, 01246-000, Brazil

  • Istituto Clinico Humanitas

    Rozzano, Lombardy, 20089, Italy

  • Istituto Europeo Di Oncologia

    Milan, Lombardy, 20141, Italy

  • Parkville Cancer Clinical Trial Unit (PCCTU)

    Melbourne, Victoria, 3000, Australia

  • Princess Margaret Hospital

    Toronto, Ontario, M5G 2M9, Canada

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • START Madrid-FJD, Hospital Fundacion Jimenez Diaz

    Madrid, 28040, Spain

  • Samsung Medical Center - PPDS

    Seoul, 06351, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, 13620, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital Yonsei University Health System - PPDS

    Seoul, 03722, South Korea

  • Stanford Health Centre - Palo Alto

    Palo Alto, California, 94304, United States

  • Universitair Medisch Centrum Groningen

    Groningen, 9713 GZ, Netherlands

  • University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center

    San Francisco, California, 94158-2545, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.